Gregory M. Glenn - Mar 6, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 6, 2023
Transactions value $
$68,248
Form type
4
Date filed
3/14/2023, 05:16 PM
Previous filing
Dec 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Purchase $22.5K +3K +35.41% $7.48 11.5K Mar 6, 2023 Direct F1, F2
transaction NVAX Common Stock Purchase $14.1K +2K +17.43% $7.04 13.5K Mar 7, 2023 Direct F3
transaction NVAX Common Stock Purchase $6.5K +1K +7.42% $6.50 14.5K Mar 10, 2023 Direct F4
transaction NVAX Common Stock Options Exercise $41.1K +6.3K +43.52% $6.52 20.8K Mar 10, 2023 Direct F5
transaction NVAX Common Stock Tax liability -$15.9K -2.43K -11.71% $6.52 18.3K Mar 10, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -6.3K -33.33% $0.00 12.6K Mar 10, 2023 Common Stock 6.3K Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2 Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5 The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F6 Each RSU represents a contingent right to receive one share of the Company common stock.
F7 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.